Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00193570
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00193453
- Locations
- 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00193076
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00193024
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colon Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193167
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
Phase 2
Completed
- Conditions
- Esophagus Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193141
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193518
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00193271
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00193011
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Phase 2
Completed
- Conditions
- Ovary Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193297